Galmed Pharmaceuticals Ltd. (GLMD)
- Previous Close
0.4000 - Open
0.3700 - Bid --
- Ask --
- Day's Range
0.3600 - 0.3949 - 52 Week Range
0.2600 - 5.6300 - Volume
20,123 - Avg. Volume
213,022 - Market Cap (intraday)
2.164M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5000 - Earnings Date May 30, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.00
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
www.galmedpharma.comRecent News: GLMD
Performance Overview: GLMD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLMD
Valuation Measures
Market Cap
2.40M
Enterprise Value
-10.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.17
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.22%
Return on Equity (ttm)
-50.63%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.91M
Diluted EPS (ttm)
-2.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
12.64M
Total Debt/Equity (mrq)
0.29%
Levered Free Cash Flow (ttm)
-3.63M